Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.

Journal of clinical pharmacy and therapeutics - 1 Dec 2015

Sohn H S, Kwon J-W, Shin S, Kim H-S, Kim H

Abstract excerpt

WHAT IS KNOWN AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib or gefitinib are indicated for the treatment of non-small cell lung cancer (NSCLC). EGFR tyrosine kinase domain mutations have been reported to be associated with EGFR-TKI response in patients with NSCLC. Certain patient subgroups in which EGFR somatic mutations are more frequently observed are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Smoking

Source

Identifiers

PMID: 26573867
DOI: 10.1111/jcpt.12332

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.PMID 26573867Read ↗

Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis.Semantic proximity Read ↗

Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations.Semantic proximity Read ↗

The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.Semantic proximity Read ↗

Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma.Semantic proximity Read ↗

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study.Semantic proximity Read ↗

EGFR mutations in non-small-cell lung cancer among smokers and non-smokers: a meta-analysis.Semantic proximity Read ↗

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.Semantic proximity Read ↗

Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC.Semantic proximity Read ↗

Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.Semantic proximity Read ↗

Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation.Semantic proximity Read ↗

Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutations.Semantic proximity Read ↗

Non-small cell lung cancer-smokers or non-smokers, does it matter?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.